KIGEN
10.8.2021 15:02:15 CEST | Business Wire | Press release
AT&T and Kigen are working together to help customers streamline their supply chains and reduce the time to market for enterprises who want to leverage SIM, embedded SIM (eSIM) and integrated SIM (iSIM) secured connectivity deep in their IoT devices.
Kigen’s SIM OS, data generation and key management services will allow AT&T to offer a broader selection for integrated SIM solutions. Manufacturers will enjoy greater flexibility by sourcing their AT&T SIM at the stage of the device manufacturing process that best suits the customer. This might be at the point of contract manufacturing, module supply, or even at the chipset level by leveraging an integrated SIM and merging both chip and SIM into a single component.
Reducing complexity and accelerating time to market will attract new customers that are embarking on their cellular IoT transformation, or those that are accelerating the adoption of secure connected goods and bringing them to market sooner as a result of streamlining the chipset and SIM evaluation process.
Prior to this, device manufacturers had to purchase multiple SIM SKUs for each end-customer or market, which has complicated global product rollouts. Access to a new cache of SIMs that are compatible with cellular chipsets and secure IC vendors offers additional flexibility that results in supply chain optimisation. This streamlined approach also simplifies the manufacturing process by allowing suppliers, OEMs and licensees to identify the ideal SIM solution earlier in the design process, meaning device estates can scale sooner upon deployment.
Kigen’s SIM OS, data generation, and key management services will enable seamless access to AT&T’s Network across LTE, LTE-M, and NB-IoT technologies. Simple integration makes it easier for new entrants and established players alike to adopt cellular IoT in their devices sooner while futureproofing them with 5G readiness.
“By working with Kigen we can help enable device manufacturers to streamline their IoT device development and manufacturing.” Said William Stovall, vice president, Mobility, IoT and 5G, AT&T. “This collaboration will also offer AT&T customers the ability to bring more innovative and secure features to market sooner.”
“Scale is both cellular IoT’s most significant opportunity and hurdle. Removing the complications of placing security at the heart of IoT devices so that businesses can focus on accelerating their products is key,” said Vincent Korstanje, CEO, Kigen. “The combination of Kigen’s solutions across all types of SIM from our ecosystem with AT&T’s connectivity simplifies how businesses choose the right type of security, tuned to their manufacturing needs; offering trusted IoT that scales.”
About Kigen
At Kigen, we are making the future of securing connectivity simple. As simple as can be. As a wholly owned subsidiary of Arm, together with our partners and customers, we are unlocking new opportunities as (integrated) eSIM becomes the cornerstone of connected devices security. Our industry-leading SIM OS products enable over 2 billion SIMs. Our remote SIM provisioning and eSIM services drive this momentum further placing us amongst top 5 SIM vendors globally. Our 135 employees globally are guided by the vision of a world where every device can connect securely and reliably. For more information, go to kigen.com or speak to us on @Kigen_Ltd on Twitter and LinkedIn about #futureofSIM.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
